Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)
ANNOUNCEMENT
UNAUDITED FINANCIAL RESULTS OF CR SANJIU FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019 AND
POSITIVE PROFIT ALERT OF CR SANJIU FOR THE YEAR
ENDED 31 DECEMBER 2019
On 29 October 2019, CR Sanjiu released its quarterly report for the nine months ended 30 September 2019 and published a positive profit alert for the year ended 31 December 2019.
China Resources Sanjiu Medical & Pharmaceutical Company Limited（華潤三九醫藥股 份有限公司）("CR Sanjiu") is a company incorporated in the People's Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to approximately 63.60% by China Resources Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") and is a subsidiary of the Company.
On 29 October 2019, CR Sanjiu released its quarterly report for the nine months ended 30 September 2019 (the "CR Sanjiu Unaudited Financials"). Set out below is the key financial information of the CR Sanjiu Unaudited Financials:
For the nine months | ||
ended 30 September | ||
2019 | 2018 | |
(RMB) | (RMB) | |
(unaudited) | (unaudited) | |
Revenue | 10,187,324,422.51 | 9,444,297,443.74 |
Net profit | 1,984,323,275.57 | 1,137,111,533.03 |
Net increase in cash and cash equivalents | -990,356,915.36 | -712,617,019.57 |
Cash and cash equivalents at the end of the period | 1,282,461,393.05 | 972,675,414.09 |
1
As of | As of | |
30 September | 31 December | |
2019 | 2018 | |
(RMB) | (RMB) | |
(unaudited) | (audited) | |
Total assets | 18,313,996,245.12 | 18,029,932,145.02 |
Total liabilities | 5,586,868,185.78 | 6,861,435,200.08 |
Owner's equity | 12,727,128,059.34 | 11,168,496,944.94 |
The CR Sanjiu Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles. For further details of the CR Sanjiu Unaudited Financials, please refer to the quarterly report for the nine months ended 30 September 2019 published by CR Sanjiu on the website of the Shenzhen Stock Exchange (www.szse.cn).
On 29 October 2019, CR Sanjiu also published a positive profit alert announcement, pursuant to which it is announced that, based on preliminary assessment by the management of CR Sanjiu and the information currently available to them, the unaudited net profit attributable to the shareholders of the listed company and basic earnings per share of CR Sanjiu for the year ended 31 December 2019 are estimated to be as follows:
For the year ended | |||
31 December | |||
2019 | 2018 | Increase | |
(unaudited) | (unaudited) | (%) | |
(Approximately) | (Approximately) | ||
Net profit attributable to the shareholders of | |||
the listed company (RMB/million) | 2,110 to 2,250 | 1,432 | 47.34 to 57.11 |
Basic earnings per share (RMB/share) | 2.16 to 2.30 | 1.46 |
2
The significant increase in CR Sanjiu's net profit attributable to the shareholders of the listed company for the year ended 31 December 2019 is primarily attributable to the completion of disposal of its 82.89% equity interest in Shenzhen Sanjiu Hospital Co., Ltd.（ 深圳市三九醫 院有限公司）in January 2019, resulting in a net gain (after tax) of approximately RMB680 million to CR Sanjiu. As CR Sanjiu is still in the processing of reviewing and finalizing its annual results for the year ended 31 December 2019, the above information has not been audited or reviewed and may be subject to adjustment or amendment. Shareholders and potential investors should refer to the final annual results and annual report for the year ended 31 December 2019 to be published by CR Sanjiu.
The financial information set out in this announcement is limited to those of CR Sanjiu only and does not provide a comprehensive presentation of the operational or financial status of the Group. Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.
By order of the Board of Directors
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Chairman
Hong Kong, 30 October 2019
As of the date of this announcement, the Board of Directors of the Company comprises Mr. WANG Chuncheng as chairman and non-executive Director, Mr. HAN Yuewei, Mr. LI Xiangming and Mdm. WENG Jingwen as executive Directors, Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi as non-executive Directors and Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.
3